Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
A Ariel, A Altraja, A Belevskiy, PW Boros… - … journal of chronic …, 2017 - Taylor & Francis
COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD
carries a significant burden, with breathlessness frequently leading to a reduction in …
carries a significant burden, with breathlessness frequently leading to a reduction in …
Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist …
GT Ferguson, P Darken, S Ballal, MK Siddiqui… - Advances in …, 2020 - Springer
Introduction Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2-
agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic …
agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic …
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
[PDF][PDF] Comparative effectiveness of drugs for chronic obstructive pulmonary disease
M Cazzola, A Segreti, P Rogliani - Drugs Today (Barc), 2012 - researchgate.net
Current guidelines for the management of chronic obstructive pulmonary disease (COPD)
recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) …
recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids (ICSs) …
Point: should triple inhaled therapy be considered in all patients with group E COPD? Yes
M Adrish, NA Hanania - Chest, 2024 - journal.chestnet.org
COPD is a heterogenous disease characterized by chronic airway inflammation and
progressive respiratory symptoms. It is currently the third leading cause of death and leads …
progressive respiratory symptoms. It is currently the third leading cause of death and leads …
Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review
GJ Rodrigo, V Plaza, JA Castro-Rodríguez - Pulmonary pharmacology & …, 2012 - Elsevier
BACKGROUND: Guidelines recommend the use of inhaled long-acting bronchodilators,
inhaled corticosteroids (ICS) and their combinations for maintenance treatment of moderate …
inhaled corticosteroids (ICS) and their combinations for maintenance treatment of moderate …
Initiation of triple therapy maintenance treatment among patients with COPD in the US
JC Simeone, R Luthra, S Kaila, X Pan… - … journal of chronic …, 2016 - Taylor & Francis
Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 …
recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 …
[HTML][HTML] Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale
H Magnussen, H Watz, A Kirsten, M Decramer… - Respiratory …, 2014 - Elsevier
Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are
recommended to decrease the risk of recurrent exacerbations in patients with Global …
recommended to decrease the risk of recurrent exacerbations in patients with Global …
Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014
J Sundh, J Åberg, M Hasselgren… - European Clinical …, 2017 - Taylor & Francis
Introduction: The aim was to investigate how the pattern of pharmacological treatment in
Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a …
Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a …